Radical-mediated intramolecular β-C(sp<sup>3</sup>)–H amidation of alkylimidates: facile synthesis of 1,2-amino alcohols
作者:Xue-Qing Mou、Xiang-Yu Chen、Gong Chen、Gang He
DOI:10.1039/c7cc08897c
日期:——
A new radical-mediated intramolecular β-C(sp3)–H amidation reaction of O-alkyl trichloro- or arylimidates is reported. Various oxazolines were efficiently prepared from easily accessible alcohol starting materials. The trichloro-oxazoline products can be hydrolyzed under mild conditions to give valuable 1,2-amino alcohols. This amidation reaction exhibits a broad substrate scope and good functional
Directed β C–H Amination of Alcohols via Radical Relay Chaperones
作者:Ethan A. Wappes、Kohki M. Nakafuku、David A. Nagib
DOI:10.1021/jacs.7b05214
日期:2017.8.2
for β C-H amination of alcohols has been developed. This approach employs a radical relay chaperone, which serves as a traceless director that facilitates selective C-H functionalization via 1,5-hydrogen atom transfer (HAT) and enables net incorporation of ammonia at the β carbon of alcohols. The chaperones presented herein enable direct access to imidate radicals, allowing their first use for H atom
已经开发了一种自由基介导的醇类 β CH 胺化策略。该方法采用自由基中继伴侣,作为无痕导向剂,通过 1,5-氢原子转移 (HAT) 促进选择性 CH 官能化,并使氨在醇的 β 碳上净结合。本文介绍的分子伴侣能够直接访问亚胺酸酯自由基,从而使其首次用于 H 原子提取。简化的方案能够将醇快速转化为它们的 β-氨基类似物(通过将醇原位转化为亚胺酸酯、定向 CH 胺化和水解为 NH2)。机械实验表明 HAT 是限速的,而分子内胺化是产物和立体决定。
Cramer et al., Chemische Berichte, 1958, vol. 91, p. 1049,1053
作者:Cramer et al.
DOI:——
日期:——
CYCLOPROPYL FUSED THIAZIN-2-AMINE COMPOUNDS AS BETA-SECRETASE INHIBITORS AND METHODS OF USE
申请人:AMGEN INC.
公开号:US20170267673A1
公开(公告)日:2017-09-21
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I:
wherein variables A
4
, A
5
, A
6
, A
8
, and each of R
a
, R
b
, R
1
, R
2
, R
3
and R
7
of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formulas II and III, and sub-formula embodiments thereof, intermediates and methods for preparing compounds of the invention.